Last SFr.79.60 CHF
Change Today -0.05 / -0.06%
Volume 2.4M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 11:43 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ann M. Fudge

Director, Member of Corporate Governance & Nomination Committee and Member of Risk Committee, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 380 board members in 12 different organizations across 18 different industries.

See Board Relationships
63SFr.500,008

Background*

Ms. Ann M. Fudge served as the Chairman and Chief Executive Officer of Young & Rubicam Brands of WPP Plc., from 2003 to 2006. Ms. Fudge served as the Chairman of Y&R Advertising, Inc. until 2011 and served as its Chief Executive Officer. She joined General Foods USA in 1986 and held several planning and marketing positions before being appointed as Executive Vice President and General Manager of the Dinners and Enhancers Division in 1991. She was employed at Mondelez ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

Former Director
Trustee
Director
Trustee
Former Vice Chairman and Member of Board of Governors
Director
Director
Former Director
Honorary Director
Director
1993-2003
Former Director
1999-Present
Independent Director and Member of Governance \ Public Affairs Committee
2001-2003
Former Director
2008-Present
Director, Member of Corporate Governance & Nomination Committee and Member of Risk Committee
2009-Present
Non-Executive Director, Member of Compensation & Management Resources Committee and Member of Nominating & Corporate Governance Committee
2009-Present
Non-Executive Director, Member of Compensation & Management Resources Committee and Member of Nominating & Corporate Governance Committee
2011-2014
Former Independent Director

Education*

MBA 1977
Harvard University
BA 1973
Simmons College

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash CompensationSFr.250,000
Total Calculated CompensationSFr.500,008
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.79.60 CHF -0.05

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman of the Board, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$1.8M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Inge G. Thulin Chairman, Chief Executive Officer and President
3M Company
$1.3M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.